Latest news

Updates from the ACCORD platform
 

Statement from the UK Early Phase platforms (TACTIC, ACCORD, CATALYST, DEFINE)

 

Profs David Jayne (TACTIC), Pam Kearns (CATALYST), Kev Dhaliwal (DEFINE), Tom Wilkinson (ACCORD), Maya Buch (MSK-TRC) and Ling-Pei Ho (Respiratory-TRC).  8 June 2020

​

The four national early phase platform trials (TACTIC, CATALYST, DEFINE and ACCORD) have today formally agreed to work as an alliance to accelerate patient recruitment, data analysis and delivery of therapeutic drugs for COVID-19 patients. They will be supported by the MSK and Respiratory TRC, the NIHR Clinical Research Network and the UK network of CRFs.

​

We will jointly review drugs and sites in a transparent manner, communicate our collaborative and common purpose to all sites that we approach, share our data at appropriate milestones, and support each other's efforts. The alliance will work closely with the NIHR BRCs and offer UK-wide early phase trials capability for the current COVID-19 and preparedness for future waves.

​

​

​

Latest news coverage
 

• The Guardian: UK hospitals to trial five new drugs in search for coronavirus treatment

                                                                                                                                   

• Reuters: BRIEF-Bergenbio: First COVID-19 Patient Dosed With Bemcentinib In Accord Trial
  
  
  
  
   

Press releases
 

• NIHR: National, collaborative platform launched to fast-track potential COVID-19 treatments

 

• Government press release: COVID-19 treatments could be fast-tracked through new national clinical trial initiative

​